Skip to main content

Prevnar 20 News

U.S. FDA Approves Prevnar 20, Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for Infants and Children

NEW YORK--(BUSINESS WIRE) April 27, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Prevnar 20®(20-valent Pneumococcal Conjugate Vaccine) ...

FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older

NEW YORK--(BUSINESS WIRE) June 08, 2021 – Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) f...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Prevnar 20 patient information at Drugs.com